Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 5;142(5):827–839. doi: 10.1007/s00401-021-02356-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Transcriptional profiling of PLAGL1-altered neuroepithelial tumor. Differential gene expression analysis between samples in the novel group (NET_PLAGL1) and a reference cohort of different glial/glioneuronal tumors (ZFTA:RELA-fused ependymoma (EPN_ZFTA), YAP1:MAMLD1-fused ependymoma (EPN_YAP1), central neurocytoma (CN), extraventricular neurocytoma (EVN), dysembryoplastic neuroepithelial tumor (DNT), papillary glioneuronal tumor (PGNT), KIAA1549:BRAF-fused pilocytic astrocytoma (PA), diffuse midline glioma H3 K27M mutant (DMG) and glioblastoma IDH wild-type (GBM). PLAGL1, IGF2 and H19 are more highly expressed in NET_PLAGL1 cases when compared with representative glial/glioneuronal tumors (a–c). GFAP levels are similar compared to different glial/glioneuronal tumors (d). Expression of markers differentially expressed in astrocytic and in ependymal tumors revealed low OLIG2 and SOX10 expression in NET_PLAGL1 compared to astrocytic/glioneuronal tumors (e, f)